ABSI is trading at $11.46 (5.2% up) following a multi-day rally driven by bullish analyst coverage and growing optimism surrounding its AI-driven biopharma platform and ABS-201 program.
- Multiple Wall Street firms have recently initiated or raised Buy ratings and price targets, contributing to a sharp move higher since June 24.
- Positive momentum continues today as investors react to the company's progress in its drug discovery pipeline and technological capabilities.